top of page

Boustead Securities Client Know Labs Begins Process to List on Major Exchange

Announces Company Highlights and Developments at its Subsidiary, Particle, Inc.

Boustead Securities, LLC (“Boustead”) client Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, through its patented and patent pending electromagnetic energy technology platforms, announced that it intends to list on a major national exchange, either NASDAQ or the NYSE, and is beginning the listing application process, with Boustead having been retained as advisor for the uplist.

Additionally, the Company highlighted recent accomplishments and issued its first public statement on the activities of its subsidiary corporation, Particle, Inc., which has, until now, been in stealth mode.

Uplist to a Major Exchange

With Boustead serving as an advisor, Know Labs has begun the process for an uplisting on a major national exchange: either NASDAQ or the NYSE. Listed companies must meet financial and liquidity requirements and satisfy corporate governance and disclosure requirements on both an initial and continuing basis.

The listing of the Company's common shares on a national exchange is subject to exchange approval and the ability of the Company to satisfy all applicable listing and regulatory requirements. While the Company intends to satisfy all of the applicable listing criteria, there is no assurance that a national exchange will approve the Company's application or that the Company will complete the listing as proposed.

Know Labs management believes uplisting to a national exchange will:

  • Provide additional opportunities to attract institutional and retail investors, allowing the Company to broaden its investor base in the United States and internationally;

  • Increase the visibility of the Company, its growth strategy, accomplishments and results to date;

  • Enable an aggressive growth strategy;

  • Increase liquidity of the Company's common shares; and

  • Raise the Company's overall profile and ultimately enhance shareholder value.

"We believe today's announcement is a significant milestone in our efforts to build Know Labs’ patented platform technology into an industry-leading provider of the next generation of continuous, real-time, non-invasive health monitoring solutions to address the unmet needs of millions of people facing challenging health conditions,” said Ron Erickson, Chairman and Founder of Know Labs. "In addition to increasing our visibility in the marketplace, the uplisting may improve the liquidity of our stock, broaden our institutional shareholder base, and augment long-term shareholder value."

Company Highlights

  • Received foundational patent on its Bio-RFID™ technology (US Patent No. 10,548,503 B2, entitled “Health Related Diagnostics Employing Spectroscopy in Radio/Microwave Frequency Band”) and continued work to expand its IP portfolio. Currently, the Company has more than 30 patents pending in their core focus on the use of electromagnetic energy to accurately identify and measure a broad range of in vivo biomolecules in the advancement of real-time, continuous health monitoring.

  • Closed a $5.7 million financing on favorable terms to support the advancement of the Company’s efforts to bring non-invasive glucose monitoring to the marketplace.

  • Developed relationships with internationally recognized clinical research institutions to perform laboratory-based validation testing to confirm internal test results.

  • Continued work on miniaturization of the Know Labs UBAND™ technology, internal testing and refinement of the use of its trade secret algorithms for exacting determination of blood glucose levels.

  • Formed the Particle, Inc. subsidiary to further expand and monetize Know Labs intellectual property.

  • Secured a team and resources to advance the Particle, Inc. commercialization activities.

Particle, Inc.

Formed in May 2020 and built upon the intellectual property of Know Labs, the independent team at Particle, Inc. has worked for the past 9 months to bring to market a disinfecting light bulb that can screw into existing fixtures in your home, office, or business. The Particle™ bulb is a hybrid light bulb that emits warm white light for everyday use and can kill viruses, bacteria, and germs, without harm to you or your family. Through internal preliminary testing, Particle, Inc. has confirmed the bulb’s efficacy in disinfecting common germs such as E. coli and Staphylococcus. A world renowned, CDC-regulated biosafety level-4 laboratory is currently testing the Particle bulb’s ability to deactivate SARS-CoV-2, the virus that causes COVID-19. Phil Bosua, Know Labs CEO and the inventor behind the first smart light bulb stated, “I had previously developed a light bulb that kills viruses and bacteria. When the coronavirus pandemic swept the world, we decided the time was right to truly revolutionize lighting as we know it. All of the internal testing we have conducted has been extremely positive and we expect results from an independent laboratory in the coming weeks. We brought together a talented team that is excited to introduce the Particle bulb to the market. It is the first of several products from Particle that I believe will make the space you inhabit safer for you and your family.”

“We believe Particle is the world’s first hybrid light bulb that blends everyday light with disinfecting power, giving it not just a pleasing aesthetic but also valuable utility, opening the door to a cleaner life.” - Phil Bosua, Know Labs, Inc. CEO


About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade under the stock symbol “KNWN.” The Company’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID™. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The Company’s first product will be the non-invasive UBAND™ Continuous Glucose Monitor (CGM). Those wishing to stay up to date on the developments at Know Labs can subscribe to the Company’s YouTube channel at this link. For more information, visit the company’s website at

About Boustead Securities, LLC

Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit

Form CRS/Reg BI Disclaimer:

Boustead Securities, LLC, Sutter Securities Inc., and Sutter Securities Clearing,LLC (SSC) are registered with the Securities and Exchange Commission (SEC) as broker-dealers and are members of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC). Brokerage and investment advisory services and fees differ and it is important for you to understand these differences. Free and simple tools are available to research firms and financial professionals at, which also provides educational materials about broker-dealers, investment advisers, and investing. When we provide you with a recommendation, we have to act in your best interest and not put our interest ahead of yours. At the same time, the way we make money creates a conflict with your interests. Please strive to understand and ask us about these conflicts because they can affect the recommendations we provide you. There are many risks involved with investing. For Boustead Securities customers and clients, please see our Regulation Best Interest Relationship Guide on the Form CRS Reg BI page on our website at For Sutter Securities’ and Sutter Securities Clearing’s customers and clients, please see the Form CRS on the website at For FlashFunders’ visitors, you may review the Form CRS of Boustead Securities, Sutter Securities and Sutter Securities Clearing under the Form CRS section. Please also carefully review and verify the accuracy of the information you provide us on account applications, subscription documents and others.

Cautionary Statement Concerning Forward-Looking Statements

This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur.

75 views0 comments


No se pudieron cargar los comentarios
Parece que hubo un problema técnico. Intenta volver a conectarte o actualiza la página.
bottom of page